[{"id":"2a3a4958-56e6-4116-af7e-25e6b74f71f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00392834","created_at":"2021-01-18T01:22:18.986Z","updated_at":"2024-07-02T16:37:10.246Z","phase":"Phase 2","brief_title":"Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma","source_id_and_acronym":"NCT00392834","lead_sponsor":"AIDS Malignancy Consortium","biomarkers":" TP53 • CFLAR","pipe":" | ","alterations":" TP53 mutation • TP53 expression • CFLAR expression","tags":["TP53 • CFLAR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 expression • CFLAR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • cyclophosphamide intravenous • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 09/01/2006","start_date":" 09/01/2006","primary_txt":" Primary completion: 07/01/2011","primary_completion_date":" 07/01/2011","study_txt":" Completion: 07/01/2013","study_completion_date":" 07/01/2013","last_update_posted":"2018-06-06"}]